Kravchuk Stanislav, Bychkov Mykola, Kozyk Marko, Strubchevska Olena, Kozyk Aleksandra
Gastroenterology, Danylo Halytsky Lviv National Medical University, Lviv, UKR.
Internal Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, USA.
Cureus. 2025 May 25;17(5):e84803. doi: 10.7759/cureus.84803. eCollection 2025 May.
Obesity presents a significant global health challenge due to its association with a range of systemic disorders. One such condition is metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), which has become the most common chronic liver disease worldwide. The prevalence of MASLD is closely linked to obesity, type 2 diabetes, and sedentary lifestyles, posing substantial risks for liver-related morbidity and extrahepatic complications such as cardiovascular and renal diseases. Despite recent advancements in pharmacological treatments, lifestyle modification remains the cornerstone of MASLD management. This review summarizes current evidence on lifestyle interventions, focusing on weight loss, dietary improvements, and increased physical activity. It also explores barriers to implementation, including socioeconomic factors, limited patient awareness, and stigma, while highlighting innovative strategies such as group-based programs, web-based interventions, and mobile technologies. As MASLD continues to rise globally, prioritizing lifestyle-based and scalable approaches will be critical to reducing its burden and improving patient outcomes.
肥胖因其与一系列全身性疾病相关联，成为了一项重大的全球健康挑战。其中一种病症是代谢功能障碍相关脂肪性肝病（MASLD），以前称为非酒精性脂肪性肝病（NAFLD），它已成为全球最常见的慢性肝病。MASLD的患病率与肥胖、2型糖尿病和久坐不动的生活方式密切相关，对肝脏相关疾病和心血管及肾脏疾病等肝外并发症构成重大风险。尽管近期药物治疗取得了进展，但生活方式的改变仍然是MASLD管理的基石。本综述总结了当前关于生活方式干预的证据，重点关注体重减轻、饮食改善和增加身体活动。它还探讨了实施过程中的障碍，包括社会经济因素、患者认知有限和耻辱感，同时强调了基于群体的项目、基于网络的干预措施和移动技术等创新策略。随着MASLD在全球范围内持续增加，优先考虑基于生活方式且可扩展的方法对于减轻其负担和改善患者预后至关重要。
